Roles and signaling pathways of CITED1 in tumors: overview and novel insights.
CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1)
diagnosis
prognosis
transactivation
transcription
treatment
tumor
Journal
The Journal of international medical research
ISSN: 1473-2300
Titre abrégé: J Int Med Res
Pays: England
ID NLM: 0346411
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
medline:
9
1
2024
pubmed:
9
1
2024
entrez:
8
1
2024
Statut:
ppublish
Résumé
CBP/p300 interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 (CITED1) is a transcriptional activator belonging to the non-DNA-binding transcription co-regulator family. It regulates diverse pathways, including the transforming growth factor/bone morphogenetic protein/SMAD, estrogen, Wnt-β-catenin, and androgen-AR signaling pathways, by binding to CBP/p300 co-activators through its conserved transactivation domain CR2. CITED1 plays an important role in embryonic development and a certain regulatory role in the occurrence and development of various tumors. In this article, the biological characteristics, expression regulation, participating signaling pathways, and potential roles of CITED1 in the clinical diagnosis and treatment of tumors are reviewed.
Identifiants
pubmed: 38190845
doi: 10.1177/03000605231220890
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3000605231220890Déclaration de conflit d'intérêts
Declaration of conflicting interestsThe authors declare that there is no conflict of interest.